Delivery Order SPE2DB24D1205-SPE2DB25FCXFU
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $25,771.74 to AmerisourceBergen Drug Corp for OFEV 150 mg capsules (60-count units) on June 18, 2025, with an ultimate completion date of July 11, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.9 billion prime vendor agreement running through December 2026 that serves as...
- The Defense Logistics Agency awarded a delivery order valued at $8,590.58 to AmerisourceBergen Drug Corp for OFEV 150 mg capsules (60-count units) on August 19, 2025, with completion targeted for September 10, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $8,590.58 to AmerisourceBergen Drug Corp for OFEV (nintedanib) 150 mg capsules (60-count units) on July 18, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order represents a non-set-aside award, indicating it was competitively procured. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract action, this delivery order is...
- The Defense Logistics Agency awarded a $8,590.58 delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of OFEV 150 mg capsules (60-unit quantity). The contract, which is non-set-aside and competitively awarded, represents a firm fixed-price delivery order with an ultimate completion date of August 4, 2025. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $25,771.74 to AmerisourceBergen Drug Corp for OFEV 150 mg capsules (60-count units) on August 18, 2025, with an ultimate completion date of September 9, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. OFEV (nintedanib) is a specialty pharmaceutical used in the treatment of pulmonary fibrosis...
- The Defense Logistics Agency awarded a $8,630.28 firm fixed-price delivery order to AmerisourceBergen Drug Corp for OFEV (nintedanib) 100 mg capsules (60-count units) on July 30, 2025, with an ultimate completion date of August 20, 2025. This non-set-aside contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a delivery order valued at $8,590.58 to AmerisourceBergen Drug Corp for OFEV (nintedanib) 150 mg capsules (60-count unit) on September 18, 2025, with an ultimate completion date of October 9, 2025. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen, a major pharmaceutical distributor and critical federal medical procurement vendor,...
- The Defense Logistics Agency awarded a delivery order valued at $8,590.58 to AmerisourceBergen Drug Corp for OFEV 150 mg capsules (60-count units) on June 2, 2025, with an ultimate completion date of June 24, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The place of performance is AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of OFEV 100 mg capsules (60-count units) valued at $8,630.28. This is a firm fixed-price delivery order with an ultimate completion date of August 21, 2025, and represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of OFEV (nintedanib) 100 mg capsules in quantities of 60 units, with a contract ceiling value of $8,630.28. This is a firm fixed-price delivery order with no set-aside designation, issued under open competition. The ultimate completion date is September 9, 2025, and the place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. OFEV...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCXFUDelivery Order
This delivery order, valued at $8,630.28 with a completion date of June 24, 2025, awards AmerisourceBergen Drug Corp the supply of OFEV 100 mg capsules (60-count units) under a Firm Fixed Price contract type with no set-aside designation. The award was issued by the Defense Logistics Agency (DLA), a defense-focused federal procurement entity, with performance to occur at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle serves as a comprehensive pharmaceutical support platform enabling the company to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs globally. OFEV (nintedanib), a specialty pharmaceutical used primarily for idiopathic pulmonary fibrosis treatment, represents one of the critical medications within AmerisourceBergen's federal pharmaceutical distribution portfolio serving the Defense Health Agency and related government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 6/2/25 |